Mobile

A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-006393-29

A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffering from dyslipidemia with uncontrolled elevated triglycerides

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess efficacy of V0002 CA 1 g at 3 capsules /day on preventing niacin-induced flushing promoted by Niaspan® administration

Critère d'inclusion

  • Dyslipidemia with uncontrolled elevated triglycerides

Liens